Asenapine News and Research

RSS
Asenapine is a new drug under development for the treatment of schizophrenia and acute mania associated with bipolar disorder.
Final results of SAPHRIS clinical study released

Final results of SAPHRIS clinical study released

Schering-Plough announces European filing of Sycrest (asenapine) for schizophrenia and bipolar I disorder

Schering-Plough announces European filing of Sycrest (asenapine) for schizophrenia and bipolar I disorder

Schering-Plough submits response to FDA for SAPHRIS (asenapine) in the acute treatment of schizophrenia and bipolar I disorder

Schering-Plough submits response to FDA for SAPHRIS (asenapine) in the acute treatment of schizophrenia and bipolar I disorder

FDA issues complete response letter for SAPHRIS (asenapine) sublingual tablets in acute treatment of schizophrenia and bipolar disorder

FDA issues complete response letter for SAPHRIS (asenapine) sublingual tablets in acute treatment of schizophrenia and bipolar disorder

FDA accepts Schering-Plough's new drug application for Asenapine

FDA accepts Schering-Plough's new drug application for Asenapine